<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597999</url>
  </required_header>
  <id_info>
    <org_study_id>15262</org_study_id>
    <secondary_id>578/2533(EC4)</secondary_id>
    <nct_id>NCT01597999</nct_id>
  </id_info>
  <brief_title>Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer</brief_title>
  <official_title>Accuracy of Magnetic Resonance Imaging (MRI) in Predicting Aggressiveness of Early Breast Cancer According to Molecular Subtypes Identified by ER PR and HER-2 Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist
      in early breast cancer with poor prognostic features.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dedicated Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>study the benefits of DCE-MRI using Gadovist in prognostic determination of early invasive breast cancer</measure>
    <time_frame>1 year</time_frame>
    <description>The benefits of breast tumor diagnosis from DCE-MRI in early invasive breast cancer with poor prognostic features</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ascertain the accuracy of pre-operative DCE-MRI in terms of detection and characterization of breast cancer, as compared to tissue biopsy.</measure>
    <time_frame>1 year</time_frame>
    <description>The comparision between DCE-MRI radiological features in early invasive breast cancer with poor prognostic features and early invasive breast cancer with good prognostic features To ascertain the accuracy of pre-operative DCE-MRI in terms of detection and charecterization of breast cancer, as compared to tissue biopsy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Invasive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features</description>
    <arm_group_label>No treatment</arm_group_label>
    <other_name>Magnetic Resonance Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with invasive ductal carcinoma

          -  Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon

          -  Breast cancer patients with pathological diagnosed invasive ductal carcinoma with
             hormonal receptor (ER, PR and HER-2) response

          -  Patients who have signed on informed consent form Patients will undergo MRI imaging
             and the physicians will practice according to practice guidelines.

        Exclusion Criteria:

          -  Patients under 18 years old or during pregnancy

          -  Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are
             allergic to MRI contrast agent Patients with unstable clinical abnormality and might
             get unexpected clinical treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pornpim Korpraphong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr.Pornpim Korpraphong, Assist.Prof.</last_name>
    <phone>6624197000</phone>
    <phone_ext>9039</phone_ext>
    <email>pfuang@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr.Pornpim Korpraphong, Assist.Prof.</last_name>
      <phone>662-4197000</phone>
      <phone_ext>9039</phone_ext>
      <email>pfuang@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr.Pornpim Korpraphong, Assist.Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>January 21, 2013</last_update_submitted>
  <last_update_submitted_qc>January 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

